Topical Ruxolitinib for Treatment of Non-segmental Vitiligo

Abstract

Ruxolitinib, a selective Janus kinase (JAK) 1 and 2 inhibitor, has emerged as a novel targeted therapy for vitiligo based on advances in understanding its immunopathogenesis. Vitiligo is driven by interferon-γ (IFN-γ)–mediated activation of the JAK–STAT signaling pathway, which promotes recruitment of autoreactive CD8⁺ T cells and subsequent melanocyte destruction. By inhibiting JAK1/2 activity, ruxolitinib effectively blocks downstream cytokine signaling, disrupts this autoimmune cascade, and creates a local environment conducive to melanocyte survival and repigmentation. Topical ruxolitinib 1.5% cream has shown promising results in clinical trials, notably the phase 3 TRuE-V1 and TRuE-V2 studies, demonstrating significant repigmentation and improved patient-reported outcomes compared with vehicle. Its favorable safety profile, minimal systemic absorption, and potential synergy with phototherapy make it a major advance in vitiligo management.